Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
>
Chemicals & Drugs
>
Amino Acid
>
Intravenous Immunoglobulins
Intravenous Immunoglobulins
Intravenous immunoglobulins (IVIGs) are a class of therapeutic products derived from pooled human plasma, containing a broad spectrum of antibodies.
They are used to treat a variety of immune-mediated disorders, such as primary immunodeficiencies, autoimmune diseases, and neurological conditions.
IVIGs provide passive immunization by supplementing the body's natural immunoglobulins, helping to modulate the immune system and reduce inflammation.
Researchers can optimize their IVIG research using AI-driven comparisons from PubCompare.ai, which analyzes data to identify the most effective products and procedures.
This streamlines IVIG research by locating the best protocols from literature, preprints, and patents, improving reproducibility and accuarcy.
They are used to treat a variety of immune-mediated disorders, such as primary immunodeficiencies, autoimmune diseases, and neurological conditions.
IVIGs provide passive immunization by supplementing the body's natural immunoglobulins, helping to modulate the immune system and reduce inflammation.
Researchers can optimize their IVIG research using AI-driven comparisons from PubCompare.ai, which analyzes data to identify the most effective products and procedures.
This streamlines IVIG research by locating the best protocols from literature, preprints, and patents, improving reproducibility and accuarcy.
Most cited protocols related to «Intravenous Immunoglobulins»
Acute Disease
Adult
Antibodies
Autonomic Nervous System Disorders
Child
Cognition
Cyclophosphamide
Encephalitis
Ethics Committees, Research
Hypoventilation
Immunotherapy
Intravenous Immunoglobulins
Memory
Movement Disorders
N-Methyl-D-Aspartate Receptors
Neoplasms
Patient Representatives
Patients
Physicians
Plasmapheresis
Puberty
Relapse
Rituximab
Seizures
Speech
Steroids
Youth
We purified platelets from whole blood (obtained from healthy volunteers) that had undergone anticoagulation with adenine citrate dextrose solution A. None of the volunteers had been taking antiplatelet drugs or had been vaccinated in the previous 10 days. We prepared platelets using methods that have been described previously.2 (link),3 (link) In a subgroup of experiments, platelets were preincubated in buffer with ChAdOx1 nCov-19 (1:2000 dilution) and washed before use. Washed platelets (75 microliters) were incubated with either buffer, a low-molecular-weight heparin (reviparin [Abbott]), or PF4 (Chromatec) in either the presence or absence of the FcγIIa receptor–blocking antibody IV.3. In some experiments, unfractionated heparin (100 IU per milliliter) was added to inhibit PF4-dependent reactions, or ChAdOx1 nCov-19 (1:50 dilution) was added per well. Serum was coincubated with PF4 and platelets in the presence of immune globulin (Privigen IVIG [CSL Behring]) at a concentration of 10 mg per milliliter. After establishing assay conditions using serum from the initial four patients, we investigated another 24 serum samples that tested positive on immunoassay to validate our findings. We refer to this modified platelet-activation test as the PF4-enhanced platelet-activation test.
To measure direct antibody binding, we used two immunoassays, a PF4–heparin enzyme-linked immunosorbent assay (ELISA) and a PF4 ELISA, with antibody binding measured by a secondary antihuman IgG, as described previously.4 (link) In addition, antibodies from two serum samples were affinity purified by immobilized PF4–heparin and immobilized PF4, and the purified antibodies were tested in the assays. (Details about this method are provided in theSupplementary Appendix , available with the full text of this article at NEJM.org.)
We defined reactivity on ELISA according to the optical-density units as strong (≥2.00), intermediate (1.00 to 1.99), or weak (0.50 to 0.99). On the PF4-enhanced platelet-activation test, reactivity was graded according to the time that had elapsed until platelet aggregation,5 (link) with shorter reaction times indicating stronger platelet activation (strong activation, 1 to 5 minutes; intermediate activation, >5 to 15 minutes; and weak activation, >15 to 30 minutes).
To measure direct antibody binding, we used two immunoassays, a PF4–heparin enzyme-linked immunosorbent assay (ELISA) and a PF4 ELISA, with antibody binding measured by a secondary antihuman IgG, as described previously.4 (link) In addition, antibodies from two serum samples were affinity purified by immobilized PF4–heparin and immobilized PF4, and the purified antibodies were tested in the assays. (Details about this method are provided in the
We defined reactivity on ELISA according to the optical-density units as strong (≥2.00), intermediate (1.00 to 1.99), or weak (0.50 to 0.99). On the PF4-enhanced platelet-activation test, reactivity was graded according to the time that had elapsed until platelet aggregation,5 (link) with shorter reaction times indicating stronger platelet activation (strong activation, 1 to 5 minutes; intermediate activation, >5 to 15 minutes; and weak activation, >15 to 30 minutes).
Adenine
Antibodies
Antibodies, Blocking
Antiplatelet Agents
Biological Assay
Blood Platelets
Buffers
Cardiac Arrest
ChAdOx1 nCoV-19
Citrates
Debility
Enzyme-Linked Immunosorbent Assay
Glucose
Healthy Volunteers
Heparin
Heparin, Low-Molecular-Weight
Immunoassay
Immunoglobulins
Intravenous Immunoglobulins
Patients
Platelet Activation
Platelet Aggregation
Privigen
reviparin
Serum
Technique, Dilution
Voluntary Workers
Change in therapy has been chosen as the reference standard for disease activity and used as the response (outcome) variable. This is based on the well-defined benchmark for active disease, which is the decision to treat and is in line with the previous study that derived the scoring for the Classic BILAG index [6 (link)].
A robust definition for change in therapy was used, similar to the definition used in our previous study [6 (link)]. Change in therapy was the change in treatment following the assessment. The medications of interest included immunosuppressives, anti-malarials, glucocorticoids, biological therapy, topical glucocorticoids, topical immunosuppressives, intravenous immunoglobulins, plasmapheresis, anti-coagulation, prasterone, thalidomide and retinoids. NSAIDs were not included as they are commonly used to treat non-lupus indications (especially for pain relief) and some could be obtained as non-prescription medication. For this analysis, change in therapy was categorized into ‘increase in therapy’ and ‘no increase in therapy’.
A robust definition for change in therapy was used, similar to the definition used in our previous study [6 (link)]. Change in therapy was the change in treatment following the assessment. The medications of interest included immunosuppressives, anti-malarials, glucocorticoids, biological therapy, topical glucocorticoids, topical immunosuppressives, intravenous immunoglobulins, plasmapheresis, anti-coagulation, prasterone, thalidomide and retinoids. NSAIDs were not included as they are commonly used to treat non-lupus indications (especially for pain relief) and some could be obtained as non-prescription medication. For this analysis, change in therapy was categorized into ‘increase in therapy’ and ‘no increase in therapy’.
Anti-Inflammatory Agents, Non-Steroidal
Antimalarials
Coagulation, Blood
Drugs, Non-Prescription
Glucocorticoids
Immunosuppressive Agents
Intravenous Immunoglobulins
Lupus Vulgaris
Pain
Pharmaceutical Preparations
Plasmapheresis
Prasterone
Retinoids
Thalidomide
Therapeutics
Therapies, Biological
To ensure that phagocytosis measured by flow cytometry resulted in actual bead uptake, and not bead attachment alone, we performed imaging flow cytometry to assess the amount of bead attachment and internalization. Immune complexes were formed with HIVIG, IVIG and no antibody control as described above. WBCs were incubated with immune complexes at 4 °C and 37 °C for 1 h. Cells from 12 wells were then pooled, washed and stained with CD66b-AF647 (Biolegend) and DAPI (Invitrogen). Bead attachment and internalization by CD66b+ cells were visualized using an ImageStreamX MkII (EMD Millipore) across 500,000 independent neutrophil events (60× objective, 405, 488 and 642 nm lasers, with extended depth of focus) and quantified using IDEAS 6 software utilizing the internalization module. An internalization feature was employed describing the ratio of fluorescence intensity of the beads inside the cell against whole cell intensity, with positive scores representing greater internalization.
Full text: Click here
Alexa Fluor 647
CEACAM8 protein, human
Cells
Complex, Immune
DAPI
Flow Cytometry
Fluorescence
HIV hyperimmune globulin
Immunoglobulins
Intravenous Immunoglobulins
Leukocytes
Neutrophil
Phagocytosis
Antibodies
Biological Assay
Enzyme-Linked Immunosorbent Assay
Gammagard
GP 140
Grafts
HIV-1
HIV-2
Homo sapiens
Infant, Newborn
Infection
Intravenous Immunoglobulins
Mus
Passive Immunization
Serum
Stem Cells, Hematopoietic
Most recents protocols related to «Intravenous Immunoglobulins»
Example 23
In this Example, the dose response of mAbXcite-cetuximab was studied. The present study utilized mAbXcite-cetuximab in which the conjugation utilized reductive amination (direct) chemistry, a 5-mer oligomer, and a load of about 3 oligomers per antibody.
In this Example, 7 week old female nude mice were implanted SC with 2.5×106 HCT-116 cells (HCT-116 is a human KRAS mutant colorectal cancer cell line). When tumor volume wan in the range of 51-80 mm3 mice were randomly divided into groups (9 mice/group) and treated with IVIG (as a source for anti-β-1,6-glucan antibodies) followed 2 hours later by vehicle control, cetuximab or mAbXcite EGFR. The dosing was determined by the half-life and was twice weekly. Various doses were assessed: 5, 10, 15 mg/kg for each antibody. Tumor volume was assessed by caliper measurement twice weekly. Body weight was monitored twice weekly. Mice were euthanized after tumors reached a volume of 2000 mm3 or if their body weight dropped by more than 15%.
Analysis of data collected form this experiment was performed. Tumor volume was calculated based on the following formula: TV (mm3)={length (mm)×width (mm)2}/2. Results are shown in
Full text: Click here
Amination
Antibodies
Body Weight
Cell Lines
Cetuximab
Colorectal Carcinoma
EGFR protein, human
Females
Figs
Glucans
HCT116 Cells
Homo sapiens
Immunoglobulins
Intravenous Immunoglobulins
K-ras Genes
Mice, Nude
Mus
Neoplasms
This retrospective cohort study was approved by the Zhengzhou University Ethics Committee (2019-KY-018). All the patients submitted written informed consent for participation. We collected the clinical data of 228 patients in the Department of Neurology of the First Affiliated Hospital of Zhengzhou University from April 2014 to April 2021. All patients met the international diagnostic criteria of anti-NMDAR encephalitis (17 (link)), with at least one of the following symptoms: (1) psychiatric disturbance, seizures, abnormal movement, speech disorder, consciousness declination, and autonomic dysfunction/central hypoventilation; (2) CSF positive for anti-NMDAR antibodies; and (3) free of other diseases. The exclusion criteria were as follows: (1) anti-NMDAR encephalitis previously diagnosed and treated with corticosteroids, intravenous immunoglobulin, immunosuppressants, plasma exchange, and other immunotherapies in other medical institutions before admission (n = 16); (2) with another comorbid serious disease, such as tumor, recurrent serious infection, recent use of anticoagulants, or other conditions affecting the nervous system (n = 11 patients); and (3) patients with incomplete data (n = 20). The screening process is shown in Figure 1 .
Full text: Click here
Adrenal Cortex Hormones
Anti-Antibodies
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Anticoagulants
Autonomic Nervous System Disorders
Consciousness
Dyskinesias
Ethics Committees
Hypoventilation
Immunosuppressive Agents
Immunotherapy
Intravenous Immunoglobulins
N-Methyl-D-Aspartate Receptors
Neoplasms
Patients
Plasmapheresis
Seizures
Speech Disorders
Systems, Nervous
Statistical details of experiments can be found in the figure legends. All REAP screens, ELISA, and neutralization assays were performed with two technical replicates. Data analysis was performed using R, Python, Excel, and GraphPad Prism. No statistical method was used to predetermine the sample size. Patients were excluded from the acute COVID-19 cohort if they did not have moderate or severe disease or if they only had a 1-time point because this would prohibit the longitudinal analysis required by our study. Patients were excluded from the vaccination cohort if an unclear sample label or obvious cross-well contamination was detected. Additionally, one patient was excluded due to failed REAP process and lack of autoantibody data. Two patients were excluded from the Myocarditis cohort: 1 patient received IVIG before their blood sample, which complicates the results of REAP, making them uninterpretable; 1 patient had onset of myocarditis 21 days after the vaccination, which is an atypical time course and thus the cause of the myocarditis (viral vs. vaccine) could not be determined. The experiments were not randomized.
For the acute COVID-19 cohort and the Benaroya cohort, REAP and ELISA/neutralization studies were performed by the investigator before receiving associated clinical annotations. For the Yale HCW cohort, CoronaVac cohort, and the myocarditis cohort, the investigator received clinical annotations at the time of REAP/ELISA/neutralization studies. However, samples were analyzed in the same manner in a randomized plate layout.
For the acute COVID-19 cohort and the Benaroya cohort, REAP and ELISA/neutralization studies were performed by the investigator before receiving associated clinical annotations. For the Yale HCW cohort, CoronaVac cohort, and the myocarditis cohort, the investigator received clinical annotations at the time of REAP/ELISA/neutralization studies. However, samples were analyzed in the same manner in a randomized plate layout.
Full text: Click here
Autoantibodies
Biological Assay
BLOOD
CoronaVac
COVID 19
Enzyme-Linked Immunosorbent Assay
Intravenous Immunoglobulins
Myocarditis
Patients
prisma
Python
Vaccination
Vaccines
ELISA plates were coated overnight with anti-human IgG (Sigma Aldrich I5260) at 1:5000 in PBS, then washed 3 times in PBS-0.05% Tween (PBST) and blocked with 5% BSA in PBS. Primary incubation was performed with serum diluted at 1:1 000 000 for 2 hours at room temperature, then plates were washed 3 times in PBST. Secondary incubation was performed with 1:20 000 dilution of HRP-conjugated anti-human IgG antibody (Sigma Aldrich SAB701283) for 1 hour at room temperature, then plates washed 3 times in PBST. Plates were developed with 1-Step™ Ultra TBM-ELISA substrate solution (Thermo Fisher) and stopped with equal volume 1N H2SO4. Absorbance was read at 450 nm with reference 570 nm. GammaGard liquid IVIG was used as a quantitative standard.
Full text: Click here
anti-IgG
Enzyme-Linked Immunosorbent Assay
Gammagard
Homo sapiens
Immunoglobulins
Intravenous Immunoglobulins
Serum
Technique, Dilution
Tweens
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Anti-Antibodies
anti-c antibody
Antibodies
Antibodies, Anti-Idiotypic
bcl-2 Gene
Biological Assay
Buffers
Caspase 3
Caspase 9
Cells
Chemiluminescence
Cytochromes
Cytoplasm
GAPDH protein, human
Gels
Horseradish Peroxidase
Intravenous Immunoglobulins
Milk, Cow's
Mitochondrial Proteins
Mus
Phenylmethylsulfonyl Fluoride
polyvinylidene fluoride
Proteins
Rabbits
Radioimmunoprecipitation Assay
SDS-PAGE
Tissue, Membrane
WISP2 protein, human
Top products related to «Intravenous Immunoglobulins»
Sourced in United States, Switzerland, Germany
Privigen is a laboratory equipment product manufactured by CSL Behring. It is an intravenous immunoglobulin (IVIG) solution used for the treatment of various medical conditions. The core function of Privigen is to provide passive immunization by supplying a broad spectrum of human antibodies derived from human plasma.
Sourced in United States
Anti-COX IV antibody is a laboratory reagent used to detect the presence and relative abundance of the COX IV protein in biological samples. COX IV is a subunit of the cytochrome c oxidase complex, which is a crucial enzyme in the electron transport chain of mitochondria. This antibody can be utilized in various analytical techniques, such as Western blotting and immunohistochemistry, to study the expression and localization of COX IV in different cell types and tissues.
Sourced in Switzerland, United States, Canada
Simulect is a laboratory equipment product manufactured by Novartis. It is designed for use in scientific research and clinical applications.
Sourced in United States, France, Canada, Germany, Ireland, Switzerland
Thymoglobulin is a polyclonal antithymocyte globulin (ATG) product developed by Sanofi. It is a sterile, purified, and concentrated immunoglobulin preparation derived from the plasma of horses immunized with human thymocytes. Thymoglobulin is used as an immunosuppressant to prevent and treat acute rejection in organ transplantation.
Sourced in United States
The GeneChip® Human Transcriptome Array 2.0 (HTA 2.0) is a genome-wide array designed to analyze the expression of protein-coding and non-coding transcripts. It provides comprehensive coverage of the human transcriptome.
Sourced in United States
Gammagard is an intravenous immunoglobulin (IVIg) product manufactured by Baxter. It is a sterile solution containing purified human immunoglobulin G (IgG) derived from human plasma. Gammagard is designed for therapeutic use to treat various immune deficiencies and autoimmune disorders.
Sourced in United States
The COX IV antibody is a laboratory reagent used to detect the presence and/or expression levels of the Cytochrome c oxidase subunit 4 (COX IV) protein. COX IV is a critical component of the electron transport chain within the mitochondria and plays a key role in cellular respiration. The COX IV antibody can be used in various experimental techniques, such as Western blotting, immunohistochemistry, and flow cytometry, to investigate the expression and localization of this important mitochondrial protein.
Sourced in United States, Germany, United Kingdom, China, Italy, Japan, France, Sao Tome and Principe, Canada, Macao, Spain, Switzerland, Australia, India, Israel, Belgium, Poland, Sweden, Denmark, Ireland, Hungary, Netherlands, Czechia, Brazil, Austria, Singapore, Portugal, Panama, Chile, Senegal, Morocco, Slovenia, New Zealand, Finland, Thailand, Uruguay, Argentina, Saudi Arabia, Romania, Greece, Mexico
Bovine serum albumin (BSA) is a common laboratory reagent derived from bovine blood plasma. It is a protein that serves as a stabilizer and blocking agent in various biochemical and immunological applications. BSA is widely used to maintain the activity and solubility of enzymes, proteins, and other biomolecules in experimental settings.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Gamunex-C is a liquid intravenous immune globulin (IVIG) product manufactured by Grifols. It is a sterile, clear, and colorless solution containing antibodies derived from human plasma. Gamunex-C is designed for administration into the bloodstream to provide passive immunization for individuals with primary immunodeficiency diseases.
More about "Intravenous Immunoglobulins"
Intravenous immunoglobulins (IVIGs) are a class of therapeutic products derived from pooled human plasma, containing a broad spectrum of antibodies.
These immunoglobulins are used to treat a variety of immune-mediated disorders, such as primary immunodeficiencies, autoimmune diseases, and neurological conditions.
IVIGs provide passive immunization by supplementing the body's natural immunoglobulins, helping to modulate the immune system and reduce inflammation.
Researchers can optimize their IVIG research using AI-driven comparisons from PubCompare.ai, which analyzes data to identify the most effective products and procedures.
This streamlines IVIG research by locating the best protocols from literature, preprints, and patents, improving reproducibilty and accuracy.
Privigen, a type of IVIG, is a treatment option for various conditions, including primary immunodeficiencies, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy.
Anti-COX IV antibody and Simulect are related biologics that can be used in conjunction with IVIG therapy.
Thymoglobulin, a polyclonal anti-T-cell antibody, is another immunotherapy that may be used in combination with IVIGs.
The GeneChip® Human Transcriptome Array 2.0 (HTA 2.0) can be utilized to analyze gene expression patterns in IVIG research.
Gammagard and Gamunex-C are other IVIG products that have been approved for the treatment of primary immunodeficiencies and other conditions.
Bovine serum albumin is sometimes used as a stabilizer in IVIG formulations.
SAS version 9.4 is a statistical software that can be employed for data analysis in IVIG studies.
Researchers can leverage the insights from these related terms and technologies to enhance their understanding and optimization of IVIG therapies.
These immunoglobulins are used to treat a variety of immune-mediated disorders, such as primary immunodeficiencies, autoimmune diseases, and neurological conditions.
IVIGs provide passive immunization by supplementing the body's natural immunoglobulins, helping to modulate the immune system and reduce inflammation.
Researchers can optimize their IVIG research using AI-driven comparisons from PubCompare.ai, which analyzes data to identify the most effective products and procedures.
This streamlines IVIG research by locating the best protocols from literature, preprints, and patents, improving reproducibilty and accuracy.
Privigen, a type of IVIG, is a treatment option for various conditions, including primary immunodeficiencies, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy.
Anti-COX IV antibody and Simulect are related biologics that can be used in conjunction with IVIG therapy.
Thymoglobulin, a polyclonal anti-T-cell antibody, is another immunotherapy that may be used in combination with IVIGs.
The GeneChip® Human Transcriptome Array 2.0 (HTA 2.0) can be utilized to analyze gene expression patterns in IVIG research.
Gammagard and Gamunex-C are other IVIG products that have been approved for the treatment of primary immunodeficiencies and other conditions.
Bovine serum albumin is sometimes used as a stabilizer in IVIG formulations.
SAS version 9.4 is a statistical software that can be employed for data analysis in IVIG studies.
Researchers can leverage the insights from these related terms and technologies to enhance their understanding and optimization of IVIG therapies.